N/A
Completed N=26
Effect of Cross Frequency tACS on Cognitive Control
Cognitive Control · Executive Function
Source: ClinicalTrials.gov NCT03800030 ↗
Enrolled (actual)
26
Serious AEs
0.0%
Results posted
May 2020
Primary outcomePrimary: Reaction Time for Trials With High Abstraction Relative to Low Abstraction — 0.1247; 0.1444; 0.1022 seconds — p=0.031
Summary
Investigation of frequency specific transcranial alternating current stimulation on cognitive control signals in frontal cortex
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reaction Time for Trials With High Abstraction Relative to Low Abstraction |
0.1247; 0.1444; 0.1022 | 0.031 sig |
| PRIMARY Reaction Time for Trials With High Set-size Relative to Low Set-size |
0.1905; 0.1853; 0.1888 | 0.935 |
| PRIMARY Delta Phase to Beta Amplitude Coupling Strength |
-0.0873; 0.1123; -0.1250 | 0.040 sig |
| PRIMARY Theta Phase to Gamma Amplitude Coupling Strength |
0.1615; 0.0706; 0.0577 | 0.020 sig |
| PRIMARY Percent Correct for Trials With High Abstraction Relative to Low Abstraction |
0.5661; -0.2944; 0.7246 | 0.540 |
| PRIMARY Percent Correct for Trials With High Set-size Relative to Low Set-size |
-2.2871; -4.3252; -4.1667 | 0.007 sig |
Eligibility Criteria
Inclusion Criteria
- Between the ages of 18 and 35 years
- Able to provide informed consent
- Willing to comply with all study procedures and be available for the duration of the study Speak and understand English
Exclusion Criteria
- Attention Deficit Hyperactivity Disorder (currently under treatment)
- Neurological disorders and conditions, including, but not limited to:
- History of epilepsy
- Seizures (except childhood febrile seizures and electroconvulsive therapy induced seizures) Dementia
- History of stroke
- Parkinson's disease
- Multiple sclerosis
- Cerebral aneurysm
- Brain tumors
- Medical or neurological illness or treatment for a medical disorder that could interfere with study participation (e.g., unstable cardiac disease, malignancy)
- Prior brain surgery
- Any brain devices/implants, including cochlear implants and aneurysm clips
- History or current traumatic brain injury
- (For females) Pregnancy or breast feeding
- Personal or family history of mental/psychiatric disorder (e.g., anxiety, major depressive disorder, schizophrenia, etc.)
- Positive urine test for the following: Marijuana (THC), Cocaine (COC), Phencyclidine (PCP), Amphetamine (AMP), Ecstasy (MDMA), Methamphetamine (Mamp), Opiates (OPI), Oxycodone (OXY), Methadone (MTD), Barbiturates (BAR), Benzodiazepines (BZO), Buprenorphine (BUP), Tricyclic Antidepressants (TCA), Propoxyphene (PPX)
- Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study
Data sourced from ClinicalTrials.gov (NCT03800030). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.